NSPR — InspireMD Income Statement
0.000.00%
- $62.21m
- $28.26m
- $6.21m
- 33
- 15
- 67
- 32
Annual income statement for InspireMD, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3.72 | 2.48 | 4.5 | 5.17 | 6.21 |
Cost of Revenue | |||||
Gross Profit | 0.756 | 0.083 | 0.754 | 1.12 | 1.81 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 13.5 | 12.9 | 19.2 | 23.9 | 27.3 |
Operating Profit | -9.82 | -10.4 | -14.7 | -18.7 | -21.1 |
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -10 | -10.5 | -14.9 | -18.5 | -19.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -10 | -10.5 | -14.9 | -18.5 | -19.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -10 | -10.5 | -14.9 | -18.5 | -19.9 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -10 | -10.5 | -14.9 | -18.5 | -19.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -72.1 | -6.97 | -2.03 | -2.35 | -0.821 |